Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled Study (BEAM)
2026년 7월 13일 업데이트: Universidade do Porto
BURDEN AND EFFICACY OF ANTICHOLINERGIC VS MIRABEGRON IN OVERACTIVE BLADDER - A RANDOMIZED CONTROLLED STUDY
Overactive bladder (OAB) is a common condition that causes a sudden, strong need to urinate, often with frequent daytime and night-time trips to the toilet, and sometimes leaking. It can have a substantial impact on everyday quality of life. Two of the most common medicines used to treat OAB work in different ways: one type (antimuscarinics, such as solifenacin) blocks a nerve signal in the bladder, while another type (beta-3 agonists, such as mirabegron) helps the bladder muscle relax.
Many people with OAB are already taking other medicines - for example, for mood, sleep, or allergies - that, without being intended for the bladder, also block that same nerve signal. The combined effect of all these medicines is called the "anticholinergic burden." Researchers want to understand whether a person's existing anticholinergic burden changes how well each OAB treatment works. The idea is that if this nerve pathway is already heavily blocked by other medicines, an antimuscarinic might be less helpful, and a treatment that works in a different way (mirabegron) might be a better choice.
In this study, adults with newly diagnosed OAB who have not yet been treated will be randomly assigned to take either solifenacin or mirabegron once a day. Before starting, each participant's anticholinergic burden will be measured using a validated tool called the Drug Burden Index (DBI) and ACB. Bladder symptoms will be assessed with a standard questionnaire (ICIQ-FLUTS) and a bladder diary at the start of treatment and again after 1 and 2 months. By comparing how participants respond depending on their baseline anticholinergic burden, the study aims to learn whether measuring this burden can help doctors choose the most effective first-line treatment for each patient.
연구 개요
연구 유형
중재적
등록 (추정된)
208
단계
- 4단계
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Adult patients with a clinical diagnosis of overactive bladder syndrome.
- Treatment-naïve for OAB pharmacotherapy (no prior antimuscarinic or mirabegron for OAB).
- Able to complete the ICIQ-OAB questionnaire and a frequency-volume chart.
- Written informed consent.
Exclusion Criteria:
Neurogenic bladder.
- Previous treatment with anticholinergics or mirabegron for OAB.
- History of pelvic radiotherapy or bladder cancer.
- Post-void residual volume > 200 mL.
- Clinically significant stress urinary incontinence.
- Chronic pelvic pain syndrome.
- Congenital urinary tract malformations.
- Prior bladder surgery; history of mid-urethral sling or prostate surgery.
- Contraindication to solifenacin or mirabegron.
- End-stage renal disease on dialysis.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Low Anticholinergic Burden - Solifenacin
Participants randomized to this arm receive solifenacin succinate 5 mg, an oral selective M3 antimuscarinic, taken once daily for 2 months.
Solifenacin reduces overactive bladder symptoms by blocking muscarinic receptor-mediated detrusor contractions.
|
Patients will receive solifenacin succinate 5 mg, an oral selective M3 antimuscarinic, taken once daily for 2 months.
Solifenacin reduces overactive bladder symptoms by blocking muscarinic receptor-mediated detrusor contractions.
|
|
활성 비교기: Low Anticholinergic Burden - Mirabegron
Participants randomized to this arm receive mirabegron 50 mg, an oral β3-adrenergic agonist, taken once daily for 2 months.
Mirabegron relieves overactive bladder symptoms through a non-anticholinergic mechanism, promoting detrusor relaxation during the storage phase.
|
Participants randomized to this arm receive mirabegron 50 mg, an oral β3-adrenergic agonist, taken once daily for 2 months.
Mirabegron relieves overactive bladder symptoms through a non-anticholinergic mechanism, promoting detrusor relaxation during the storage phase.
|
|
활성 비교기: High Anticholinergic Burden - Mirabegron
Participants randomized to this arm receive mirabegron 50 mg, an oral β3-adrenergic agonist, taken once daily for 2 months.
Mirabegron relieves overactive bladder symptoms through a non-anticholinergic mechanism, promoting detrusor relaxation during the storage phase.
|
Participants randomized to this arm receive mirabegron 50 mg, an oral β3-adrenergic agonist, taken once daily for 2 months.
Mirabegron relieves overactive bladder symptoms through a non-anticholinergic mechanism, promoting detrusor relaxation during the storage phase.
|
|
실험적: High Anticholinergic Burden - Solifenacin
Participants randomized to this arm receive solifenacin succinate 5 mg, an oral selective M3 antimuscarinic, taken once daily for 2 months.
Solifenacin reduces overactive bladder symptoms by blocking muscarinic receptor-mediated detrusor contractions.
|
Patients will receive solifenacin succinate 5 mg, an oral selective M3 antimuscarinic, taken once daily for 2 months.
Solifenacin reduces overactive bladder symptoms by blocking muscarinic receptor-mediated detrusor contractions.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
ICIQ OAB
기간: From enrollment to 4 and 8 weeks
|
This measure captures how much overactive bladder symptoms change after two months of treatment.
The ICIQ-OAB (International Consultation on Incontinence Questionnaire - Overactive Bladder) is a validated, patient-completed questionnaire covering the core symptoms of the condition: daytime urinary frequency, night-time urination (nocturia), urgency, and urgency-related leakage.
The four symptom items are summed into a total score ranging from 0 to 16, where a higher score means more severe symptoms.
Participants complete the questionnaire at the start of treatment (baseline) and again at 2 months; the outcome is the change between these two time points, with a larger reduction indicating greater symptom improvement.
The two treatment arms are compared using an analysis of covariance (ANCOVA) adjusted for each participant's baseline score, performed separately within the high anticholinergic burden group (Drug Burden Index ≥ 1) and the low burden group (DBI < 1).
|
From enrollment to 4 and 8 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Responder rate at Month 2
기간: From enrollment to 8 weeks
|
This measure reports the proportion of participants who achieve a clinically meaningful improvement in symptoms.
A participant is classified as a "responder" if their ICIQ-OAB total score falls by at least 3 points from baseline to 2 months - a reduction generally regarded as noticeable and worthwhile to patients.
The outcome is the percentage of responders in each treatment arm.
|
From enrollment to 8 weeks
|
|
Change in frequency-volume chart parameters at Month 2
기간: From enrollment to 8 weeks
|
A frequency-volume chart (bladder diary) is a record that participants keep at home, noting the time and volume of each urination over a defined period.
From this diary, three parameters are measured at baseline and at 2 months, and the change between them is reported: (1) the number of urinations per 24 hours; (2) the number of night-time urination episodes (nocturia); and (3) the average volume passed per urination (in millilitres).
Fewer urinations and fewer nocturia episodes, together with a larger average voided volume, indicate symptom improvement.
|
From enrollment to 8 weeks
|
|
Treatment discontinuation rate
기간: From enrollment to the end of 8 weeks
|
This measure reports the proportion of participants in each arm who stop their assigned treatment before completing the 2-month study period, for any reason (for example, side effects, lack of benefit, or personal choice).
It is expressed as a percentage of participants randomized to that arm and serves as an indicator of how well each treatment is tolerated and accepted in practice.
|
From enrollment to the end of 8 weeks
|
|
Incidence of adverse events
기간: From enrollment to the end of 8 weeks
|
This measure records the number and type of adverse events - any unwanted or harmful medical occurrence reported by participants or observed by the study team - during treatment.
Adverse events are collected at each follow-up visit through 2 months and summarized by arm, including the proportion of participants experiencing at least one event.
This outcome describes the safety and tolerability profile of each treatment.
|
From enrollment to the end of 8 weeks
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Treatment-by-DBI-stratum interaction on ICIQ-OAB change at Month 2
기간: From enrollment to the end of 8 weeks
|
This exploratory analysis examines whether the difference in effectiveness between the two treatments depends on a participant's baseline anticholinergic burden - that is, whether one treatment works comparatively better in the high-burden group (DBI ≥ 1) and the other in the low-burden group (DBI < 1).
It is assessed by testing the statistical interaction between treatment arm and DBI stratum for the change in ICIQ-OAB total score at 2 months.
This analysis is hypothesis-generating only; the study is not designed with sufficient statistical power to confirm such an interaction.
|
From enrollment to the end of 8 weeks
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
2026년 7월 1일
기본 완료 (추정된)
2027년 7월 1일
연구 완료 (추정된)
2027년 8월 1일
연구 등록 날짜
최초 제출
2026년 7월 13일
QC 기준을 충족하는 최초 제출
2026년 7월 13일
처음 게시됨 (실제)
2026년 7월 17일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
2026년 7월 17일
QC 기준을 충족하는 마지막 업데이트 제출
2026년 7월 13일
마지막으로 확인됨
2026년 6월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- BEAM
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
아니
미국 FDA 규제 기기 제품 연구
아니
미국에서 제조되어 미국에서 수출되는 제품
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .